Stockscreener 앱 받기
0.504
2.04%
0.0042
Vaxart Inc 주식(VXRT)의 최신 뉴스
Vaxart Approves Resolutions to Narrow Proposed Reverse - GlobeNewswire
Vaxart seeks approval for reverse stock split to retain Nasdaq listing By Investing.com - Investing.com South Africa
Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback - Nasdaq
Vaxart Board Approves Reverse Split Proposal - TipRanks
Vaxart seeks approval for reverse stock split to retain Nasdaq listing - Investing.com Nigeria
Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs - MSN
Vaxart (VXRT) Eyes Reverse Stock Split to Secure Nasdaq Listing | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting | VXRT Stock News - GuruFocus
Vaxart Makes Last-Minute Changes to Reverse Split PlanCritical Nasdaq Deadline Approaches - Stock Titan
Vaxart gets nod to expand COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart (VXRT) Secures BARDA Approval for Next Phase of COVID-19 Vaccine Trial | VXRT Stock News - GuruFocus
Vaxart Receives BARDA Approval for Phase 2b Trial - TipRanks
Vaxart gets nod to expand COVID-19 pill vaccine trial - Investing.com Australia
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Revolutionary Oral COVID Pill Vaccine Gets $460M BARDA Backing for Massive 10,000-Patient Trial - Stock Titan
Vaxart (VXRT) Rises After Positive Trial Results for Norovirus V - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b - GlobeNewswire
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Vaxart (VXRT) Unveils Promising Results from Phase 2b Norovirus Vaccine Study | VXRT Stock News - GuruFocus
Vaxart (VXRT) Appoints New CFO Amid Leadership Change | VXRT Sto - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine - The Manila Times
Revolutionary Oral Pill Vaccine Reduces Norovirus Infection by 30% in Landmark Phase 2b Trial - Stock Titan
Vaxart, Inc. (NASDAQ:VXRT) Q1 2025 Earnings Call Transcript - Insider Monkey
Vaxart Inc (VXRT) Q1 2025 Earnings Call Highlights: Strategic Progress Amidst Challenges - Yahoo Finance
Vaxart Inc Q1 2025 Earnings: EPS of -$0.10 and Revenue of $9.55 Million Meet Estimates - GuruFocus
Vaxart Reports Q1 2025 Progress and Financials - TipRanks
Vaxart (VXRT) Advances COVID-19 and Norovirus Vaccine Trials - GuruFocus
Vaxart Q1 2025 Earnings Call Transcript - MarketBeat
Vaxart Q1 Net Loss Narrows, Revenue Rises; Jeroen Grasman Named CFO - marketscreener.com
Vaxart Appoints Jeroen Grasman as New CFO - TipRanks
Vaxart Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxart appoints Jeroen Grasman as new CFO - Investing.com Australia
Vaxart appoints Jeroen Grasman as new CFO By Investing.com - Investing.com Nigeria
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Vaxart, Inc. SEC 10-Q Report - TradingView
Vaxart Unlocks $460M COVID Vaccine Trial Funding, Reports Strong Pipeline Progress in Q1 2025 - Stock Titan
Vaxart Appoints Jeroen Grasman as Chief Financial Officer - GlobeNewswire
Vaxart (VXRT) Proposes Reverse Stock Split to Maintain Nasdaq Li - GuruFocus
Vaxart Proposes Reverse Stock Split to Avoid Delisting - TipRanks
Vaxart, Inc. Encourages Stockholders to Approve Reverse Stock Split Proposal to Maintain Nasdaq Listing - Nasdaq
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement - GlobeNewswire
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Vaxart Resumes COVID-19 Vaccine Trial After Government Lift - TipRanks
Vaxart (VXRT) Advances Vaccine Efforts Amid Market Challenges | - GuruFocus
Vaxart seeks stockholder approval for reverse split - Investing.com
Vaxart seeks stockholder approval for reverse split By Investing.com - Investing.com Australia
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress - The Manila Times
0.78%
0.06%
자본화:
|
볼륨(24시간):